Picard Medical, Inc. (PMI)
NYSEAMERICAN: PMI · Real-Time Price · USD
3.640
+0.210 (6.12%)
Aug 10, 2026, 4:00 PM EDT - Market closed
Picard Medical Earnings Call Transcripts
Fiscal Year 2025
-
PAPZIMEOS launch drove a 149% revenue increase in 2025, with Q1 2026 sales expected to exceed $18 million. Broad payer coverage, strong physician uptake, and a permanent J-code are accelerating adoption, positioning the therapy as the new standard of care for adult RRP.
-
Picard Medical, via SynCardia, leads the total artificial heart market with the only FDA-approved device, strong clinical outcomes, and a focus on US and international expansion. Innovation efforts target a fully implantable heart by 2029, with ongoing label expansion and robust patient support.